In conclusion, this study found that colitis drives mild to moderate inflammation in the brain and increased inflammatory cytokines in the serum, and that colonic and neuroinflammation were mitigated by prophylactic treatment with the S100A9 inhibitor paquinimod. The gene discussed is S100A9; the disease is colitis.